Heron (HRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Heron Therapeutics Inc (HRTX)

Heron Therapeutics (HRTX) is actively expanding its product portfolio through hospital supplies and non-opioid analgesics, moving away from a narrow specialization in supportive care. Simultaneously, the business is implementing sustainable water cycles and reducing its carbon footprint in logistics. The current EV/EBITDA multiple is 0.00. The company's price chart demonstrates its leadership position in the segment of extended-release anti-nausea and pain medications, protected by a unique polymer delivery system.

HRTX Heron Therapeutics, Inc.: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 11/16/2026

HRTX (Heron): analytical breakdowns and indicator data

- stock price and consensus target price:
- market capitalization indicators:
Summary company analytics:HRTX (Heron Therapeutics Inc)
Original product of Heron Therapeutics, Inc.

The multiple compares the total enterprise value (assets plus debt minus cash) with operating profit before taxes and depreciation. This ratio measures the speed of capital payback, reacting sensitively to borrowing costs and operating expenses. For Heron Therapeutics (HRTX), this calculation is critical during the transition from losses to drug monetization and cost optimization. The trend of the EV/EBITDA multiple for this capital-intensive enterprise determines the current investment attractiveness of the company.

Competitor analysis

Incyte Corporation - Enterprise Value to EBITDA Ratio|hutch-med.com (HCM) - Company Value to EBITDA|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Day One Biopharmaceuticals, Inc.|Monopar Therapeutics (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (i-mabbiopharma.com) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio fennecpharma.com (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nuvectis Pharma, Inc (NVCT)|CHRS - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Corbus Pharma CRBP|Cardiff Oncology, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BYSI - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA bioatla.com|LIXT: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Citius Pharmaceuticals CTXR|Enterprise Value to EBITDA Ratio CLRB|Company Value to EBITDA BioLineRx Ltd. BLRX|Enterprise Value to EBITDA Ratio CANF (Can-Fite BioPharma)|APRE (Aprea) - Business Value to Operating Income Before Depreciation|Kazia Therapeutics Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion)|NuCana - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix, Inc)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Pharma (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Corp (PRTG)